Sphingosine-1-Phosphate Improves the Biological Features of Mouse Bone Marrow-Derived EPCs Partially through PI3K/AKT/eNOS/NO Pathway

Xia Wang 1,2,†, Enxin Zhan 3,†, Guohua Lu 4, Qingjie Mu 5, Tianliang Zhang 6,* and Nana Yang 6,7,*

1 School of Public Health and Management, Weifang Medical University, Weifang 261053, China
2 Collaborative Innovation Center of Prediction and Governance of Major Social Risks in Shandong, Weifang Medical University, Weifang 261053, China
3 Institute of Preschool Education, Jinan Preschool Education College, Jinan 250307, China
4 Department of Psychology, Weifang Medical University, Weifang 261053, China
5 School of Clinical Medicine, Weifang Medical University, Weifang 261053, China
6 Experimental Center for Medical Research, Weifang Medical University, Weifang 261053, China
7 School of Bioscience and Technology, Weifang Medical University, Weifang 261053, China

* Correspondence: burke1981@163.com (T.Z.); benben1980@126.com (N.Y.);
Tel.: +86-536-8462461 (T.Z. & N.Y.); Fax: +86-536-8462550 (T.Z. & N.Y.)
† These authors contributed equally to this work.

Received: 22 May 2019; Accepted: 28 June 2019; Published: 29 June 2019

Abstract: Sphingosine-1-phosphate (S1P), a bioactive sphingolipid, is recognized as a critical regulator in physiological and pathophysiological processes of atherosclerosis (AS). However, the underlying mechanism remains unclear. As the precursor cells of endothelial cells (ECs), endothelial progenitor cells (EPCs) can prevent AS development through repairing endothelial monolayer impaired by proatherogenic factors. The present study investigated the effects of S1P on the biological features of mouse bone marrow-derived EPCs and the underlying mechanism. The results showed that S1P improved cell viability, adhesion, and nitric oxide (NO) release of EPCs in a bell-shaped manner, and migration and tube formation dose-dependently. The aforementioned beneficial effects of S1P on EPCs could be inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor of LY294002 and nitric oxide synthase (NOS) inhibitor of N’-nitro-L-arginine-methyl ester hydrochloride (L-NAME). The inhibitor of LY294002 inhibited S1P-stimulated activation of phosphorylated protein kinase B (AKT) (p-AKT) and endothelial nitric oxide synthase (eNOS) (p-eNOS), and down-regulated the level of eNOS significantly. The results suggest that S1P improves the biological features of EPCs partially through PI3K/AKT/eNOS/NO signaling pathway.

Keywords: sphingosine-1-phosphate; endothelial progenitor cells; atherosclerosis

1. Introduction

The impairment in vascular endothelial function induced by risk factors (such as hypertension, hyperlipidemia, and hyperglycemia), is an important initial event for the onset and progression of atherosclerosis (AS) [1]. Endothelial progenitor cells (EPCs) derived from peripheral blood or bone marrow can differentiate into mature endothelial cells (ECs) and migrate to injured sites to promote endothelium repair and neovascularization in the vessel wall, and thus preventing AS progression [2–4]. However, AS could result in an obvious decrease in the quantity and function of EPCs [5]. It is reported that EPCs in AS patients fail to repair the injured endothelium, which breaks the physiological equilibrium between endothelial damage and regeneration. Therefore, improvement in the quantity and function such as
proliferation, migration, adhesion, tube formation, and nitric oxide (NO) production of EPCs is conducive to repair the injured endothelial monolayer [5,6], and thus inhibiting the initiation and progression of AS.

Sphingosine-1-phosphate (S1P), a bioactive glycosphingolipid, regulates diverse physiological functions in different organ systems. The highest level of S1P was observed in blood, particularly in high density lipoproteins (HDL) and red blood cells [7,8]. Within the cardiovascular system, S1P mediates various activities including cardioprotection following ischemia/reperfusion injury, anti-inflammation, endothelial function improvement, anti-oxidation, anti-AS, and antithrombus [9,10]. Patient-derived EPCs showed significantly impaired capacity for neovascularization in a mouse model of hind limb ischemia [11,12]. After being pretreated with S1P for 2 h before intravenous infusion, patient-derived EPCs significantly improved blood flow recovery in ischemic hind limbs [13].

The signaling pathway of S1P/S1P receptors/Src kinases/ protein kinase B (AKT)-induced NO synthesis protected EPCs from apoptosis, and S1P/S1P receptors/Src kinases/ C–X–C chemokine receptor type 4 (CXCR4) -mediated signaling was essential for homing and functional integration of EPCs to ischemic tissues [14]. Src-family tyrosine kinases can activate the phosphatidylinositol 3-kinase (PI3K)/AKT/ endothelial nitric oxide synthase (eNOS) signaling pathway [15], and the integral PI3K/AKT/eNOS/ nitric oxide (NO) pathway seems to play a vital role in improving the function of EPCs [16]. It is generally accepted that maintaining the integrity of eNOS pathway plays an important role in mobilization, proliferation, and migration of EPCs as well as vessel formation [16,17]. The major upstream effectors of eNOS pathway include phosphatidylinositol-3 kinase (PI3K) and protein kinase B (PKB/AKT). Here we hypothesize that S1P may exert its anti-AS activity through improving the biological features of EPCs to restore damaged intima. The present study found that S1P significantly improves the biological features of EPCs partially through PI3K/AKT/eNOS/NO signaling pathway.

2. Results

2.1. Isolation and Identification of Endothelial Progenitor Cells

After being isolated and cultured in an endothelial growth medium-2 MV (EGM-2MV) medium for seven days at 37 °C with 5% CO\textsubscript{2}, mononuclear cells (MNCs) derived from mouse bone marrow showed cobblestone-like morphology (Figure 1a). These cells could take DiI-ac-LDL (Figure 1b) and bind FITC-UEA (Figure 1c), which can be used to indicate differentiated EPCs. The expression of EPCs markers, such as CD133 (Figure 1d) and FLK-1 (Figure 1e), were detected after being cultured for 21 days.

![Figure 1.](image-url) Identification of endothelial progenitor cells (EPCs) derived from mouse bone marrow. The mononuclear cells (MNCs) isolated from mouse bone marrow show the characteristics of EPCs gradually: (a) EPCs showed cobblestone-like morphology (×10) after being isolated and cultured in an EGM-2MV medium for 7 days at 37 °C with 5% CO\textsubscript{2}; (b) EPCs took up DiI-ac-LDL (×10); (c) EPCs bound FITC-UEA (×10); (d) identification of EPCs by immunofluorescence for CD133 (×20) after culture for 21 days at 37 °C with 5% CO\textsubscript{2}; (e) identification of EPCs by immunofluorescence for FLK-1 (×20) after culture for 21 days at 37 °C with 5% CO\textsubscript{2}.
2.2. S1P Improves the Biological Features of EPCs

The EGM-2MV medium was replaced with a M199 medium added with 3% fetal bovine serum (FBS) before EPCs were subjected to the treatment of S1P (0–10 µM) for 24 h at 37 °C with 5% CO₂. We found that S1P significantly improved cell viability (Figure 2A), adhesion (Figure 2B), and NO release (Figure 2C) in a bell-shaped manner, and migration (Figure 2D) as well as tube formation (Figure 2E) of EPCs dose-dependently. Interestingly, S1P improved the biological features of EPCs most effectively at a concentration of 1 µM among the studied ones in the present work.

2.3. LY294002 and L-NAME Partially Suppress S1P-Promoted Biological Features of EPCs

To detect whether the improved biological features of EPCs by S1P are through PI3K/AKT/eNOS/NO signaling pathway, EPCs were pretreated with LY294002 (30 µM) or N′-nitro-L-arginine-methyl ester hydrochloride (L-NAME) (200 µM) for 2 h at 37 °C with 5% CO₂, and then incubated with S1P (1 µM). The results showed that LY294002 and L-NAME significantly suppressed the promoting effects of S1P on cell viability (Figure 3A and Figure S1), adhesion (Figure 3B),
NO release (Figure 3C), migration (Figure 3D), and tube formation (Figure 3E) of EPCs, with LY294002 more effectively than L-NAME. Both of them attenuated the S1P-promoted improvement in NO generation and tube formation of EPCs (Figure 3C).

**Figure 3.** LY294002 and N’-nitro-L-arginine-methyl ester hydrochloride (L-NAME) suppress S1P-promoted improvement in biological features of EPCs. EPCs were pretreated with LY294002 (30 μM) or L-NAME (200 μM) for 2 h at 37 °C with 5% CO2, and then incubated with S1P (1 μM) for 24 h. Cell viability (A), adhesion (B), nitric oxide (NO) release (C), migration (D), and tube formation (E) of EPC were evaluated as aforementioned. (F) Representative micrograph of EPCs migration after treatment (×100, corresponding to treatment conditions of non-treated, S1P, S1P + LY294002, and S1P + L-NAME from left to right, respectively). (G) Representative micrograph of complete tubes after treatment (×40, corresponding to treatment conditions of non-treated, S1P, S1P + LY294002, and S1P + L-NAME from left to right, respectively).

2.4. S1P Activates AKT and eNOS Phosphorylation

To investigate the underlying mechanism by which S1P improves the biological features of EPCs, we analyzed its effects on PI3K/AKT/eNOS signaling pathway at different time points (0–1 h) by Western blotting assay. The results showed that levels of phosphorylated AKT (p-AKT), phosphorylated eNOS (p-eNOS), and eNOS were significantly up-regulated with time duration (15–60 min) in the presence of S1P at 1 μM (Figure 4A–D). Among the treatment concentrations employed in the present study, S1P at 1 μM up-regulated levels of p-AKT and p-eNOS at 60 min (Figure 4E–H) most effectively.
**Figure 4.** S1P up-regulates the levels of phosphorylated AKT (p-AKT), phosphorylated endothelial nitric oxide synthase (p-eNOS), and eNOS. Effects of S1P at different time duration (A–D) (*p < 0.05, **p < 0.01 versus 0 min) or concentration (0–2 μM) (E–H) on levels of p-AKT, p-eNOS, and eNOS in EPCs were investigated by Western blot analyses.

### 2.5. LY294002 Inhibits The Levels of p-AKT, p-eNOS, and eNOS Promoted by S1P

EPCs were pretreated with LY294002 (30 μM) at 37 °C with 5% CO₂ for 2 h, and then incubated with S1P at 1 μM for 1 h. As is shown in **Figure 5**, LY294002 significantly inhibited the activation of AKT and eNOS induced by S1P (Figure 5A–D).

**Figure 5.** LY294002 inhibits S1P-induced activation of p-AKT, p-eNOS, and eNOS in EPCs. Western blot analyses of p-AKT, p-eNOS, and eNOS in EPCs treated with S1P at 1 μM or S1P at 1 μM plus LY294002 at 30 μM (A–D) were performed.
3. Discussion

EPCs originate from hemangioblast existing in peripheral blood or bone marrow [18] and express cell surface markers similar to those of mature ECs [19]. Endothelial damage is an important early step in the pathogenesis of AS [20]. It is suggested that impaired EPCs population can negatively affect the cardiovascular system, and a decreased quantity of EPCs in patients is associated with an increased risk for endothelial injury and a progression of AS plaque [3]. In the case of endothelial damage, bone marrow-derived EPCs enter the circulation and migrate to the injury site, which potentially inhibits AS and relevant complications by restoring endothelial function and promoting neoangiogenesis [21,22].

Endothelial dysfunction serves as a primary initial factor and contributes to the development of AS and other vascular diseases. EPCs promote the repair of damaged endothelium, inhibit AS development and stimulate neovascularization in ischemic tissue [22,23]. It was reported that restoration of blood flow in peripheral artery disease and recovery of left ventricular function were facilitated by autologous transplantation of cultured EPCs derived from the bone marrow of patients with coronary artery disease (CAD) [24]. However, risk factors for CAD and severe heart failure have shown to be detrimental to circulating blood-derived EPCs, and thus limiting the capacity of isolated EPCs to facilitate blood flow recovery after infusion [24]. Likewise, significantly impaired capacity for homing and neovascularization of bone marrow-derived EPCs isolated from patients with chronic ischemic heart disease was also demonstrated [24,25].

The migration is essential for circulating EPCs homing, and the survival demonstrated impaired by the risk factors for cardiovascular disease [26]. The adhesion capability of EPCs to vascular endothelium and extracellular matrix plays a vital role in angiogenesis [27]. Tube formation assay can be employed to assess the ability of EPCs for new vessel formation [28]. The characteristic early shortage of NO and relevant biomolecules related to AS progression were well reported [29]. Severe AS can be induced by chronically inhibited NO as well as high cholesterol diet [30]. NO could exert anti-AS effects via suppressing the adhesion of monocyte to endothelium and chemotaxis of smooth muscle cells [31].

S1P is one of the most vital metabolites of sphingolipids ubiquitous in mammalian membranes and possesses five specific cell surface G-protein-coupled receptors (S1PR1–S1PR5) [32,33]. S1P exerts diverse effects on monocyte attachment and migration, along with cell viability of smooth muscle cells, which is vital to AS development [34]. S1P levels in serum of patients with peripheral artery disease and carotid stenosis were reported significantly lower than those in healthy volunteers [25,34]. S1P can inhibit the adhesion of leukocytes to ECs and subsequent transmigration, as well as the production of proinflammatory mediators in ECs. In addition, it can activate eNOS [20]. S1P/S1P receptors/ Src kinases/CXCR4 receptor-mediated signaling was essential for homing and functional integration of EPCs to ischemic tissues [14]. Kimura et al. found that S1P receptor agonist of FY720 (fingolimod) promoted the migration and bone marrow homing of human CD34+ progenitor cells induced by stromal cell derived factor-1 (SDF-1) [35]. Zhao et al. demonstrated that S1P restored the bone marrow-derived progenitor cells (BMPCs)-induced endothelial barrier protection through Rac1 and Cdc42 signaling pathway [36]. S1P induced the migration and angiogenesis of EPCs through S1PR3/PDGFR-beta/AKT signaling pathway [37]. S1P-dependent pathways are reported critical for the angiogenic/vasculogenic activity of endothelial colony forming cells formed from human bone marrow [38]. However, effects of S1P on EPCs derived from bone marrow were still unclear. The activation of AKT and eNOS in PI3K/AKT/eNOS pathway was reported to play a vital role in survival and functioning of EPCs [39,40]. Similarly, PI3K/AKT/eNOS pathway was reported to be a downstream target for the angiogenesis properties of S1P [41]. In addition, S1P promotes the proliferation and attenuates apoptosis of EPCs via S1PR1/S1PR3/PI3K/AKT pathway [42]. In the present work, S1P improved the cell viability, migration, adhesion, tube formation, and NO release of EPCs, and activated the phosphorylation of both AKT and eNOS in a dose-dependent manner by and large, with most effective action concentration at 1 µM. Interestingly, S1P exerted its promoting effects on cell viability, adhesion, and NO release of EPCs in a bell-shaped manner, consistent with several previous studies finding that many endogenous compounds exhibited bell-shaped mode of action when used exogenously in several cell lines [43–45].
Pretreatment with LY294002 or L-NAME inhibited the promoting effects of S1P on EPCs, and LY294002 worked more effectively than L-NAME. These results suggest that S1P may facilitate EPCs through other downstream signal pathways of PI3K/AKT, except for those dependent on PI3K/AKT/eNOS/NO. PI3K Inhibitor inhibited NO release from EPCs treated by S1P, suggesting the dependence of NO generation on AKT activation.

In conclusion, S1P improves cell viability, migration, adhesion, tube formation, and NO release of EPCs partially through PI3K/AKT/eNOS/NO pathway. S1P agonists may be employed in clinical progenitor cell therapy to improve EPCs function in patients with CAD through activating PI3K/AKT/eNOS/NO signaling pathway. Since S1P possesses five specific cell surface receptors, knowing which receptor(s) play(s) an important role in improving the biological features of EPCs is something that needs further investigation.

4. Materials and Methods

4.1. Isolation and Culture of EPCs Derived from C57 Mice Bone Marrow

C57 mice, four to eight weeks old, were purchased from the Vital River Laboratory (Beijing, China). All animal-use protocols were reviewed and approved by the Animal Care and Use Committee of Weifang Medical University. This study was approved by the Animal Experimental Ethics Committee of Weifang Medical University. The mice were humanely sacrificed by cervical dislocation after being anesthetized by isoflurane (Sigma, catalog number: Y0000858, St. Louis, MO, USA). The whole bone marrow from the femurs and tibias of the mice was prepared by flushing medium-2MV (EGM-2MV, Lonza, catalog number: CC-3162, Basel, Switzerland), using a sterilized syringe. Bone marrow mononuclear cells (MNCs) were isolated by density gradient centrifugation using Histopaque 1083 (Sigma, St. Louis, MO, USA, catalog number: 10831) according to the manufacturer’s instructions. The isolated MNCs were seeded in fibronectin-coated six-well plates (Corning, catalog number: 3524, New York, NY, USA) at a density of 10^6/cm^2 and cultured in endothelial cell growth medium-2MV (EGM-2MV) at 37 °C with 5% CO_2 in a humidified incubator. After 72 h of culture, non-adherent cells were removed by replacing the culture fluid with fresh culture medium thoroughly and the medium was changed every three days. MNCs differentiated into late outgrowth EPCs in about 21 days.

4.2. Immunocytochemistry

After being cultured for 10 days, MNCs were incubated with 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate-labeled acetylated low-density lipoprotein (DiI-ac-LDL, Peking Union-Biology Co. Ltd, Beijing, China, catalog number: N/A) (2.5 mg/mL) for 2 h at 37 °C, and then fixed with 2% paraformaldehyde (Sigma, catalog number: P6148,) for 5 min. Thereafter, the cells were washed with DPBS (ThermoFisher, Waltham, MA, USA, catalog number: 14190250) for three times and incubated with FITC-UEA (10 mg/L, Sigma, catalog number: L9006) for 30 min at 37 °C. Then a representative micrograph was acquired by a fluorescence microscope (Olympus, Tokyo, Japan).

4.3. EPCs Treatment

Before being treated with S1P (Sigma, catalog number: 73914), the EGM-2MV medium was changed to M199 medium (Hyclone, catalog number: SH30253.01, Thermo Fisher Scientific, Waltham, MA, USA) with 3% FBS (ThermoFisher, catalog number: 10100), and these cells were divided into four groups and treated as follows: Control group (M199 + 3% FBS), S1P group (M199 + 3% FBS +
0–10 µM S1P), S1P + LY294002 (M199 + 3% FBS + 1 µM S1P + 30 µM LY294002), and S1P + L-NAME (M199 + 3% FBS + 1 µM S1P + 200 µM L-NAME). EPCs were pretreated with the PI3-kinase inhibitor of LY294002 (Sigma, catalog number: L9908) at 30 µM or NOS inhibitor of L-NAME (Sigma, catalog number: N5751) at 200 µM for 2 h and then treated with S1P for 24 h.

4.4. Cell Viability of EPCs

Cell viability of EPCs was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma, catalog number: 11465007001) assay based on the formazan transformed from MTT by viable cells. The cells were treated as mentioned previously and seeded in 96-well plates at a density of 10^3 cells/cm². Twenty microliters MTT (5 mg/mL) was added to every well, followed by being cultured at 37 °C with 5% CO₂ for 4 h. Then 150 µL dimethylsulfoxide (DMSO) (Gibco, Grand Island, NY, USA, catalog number: D12345) used to dissolve the insoluble formazan crystals existing in viable cells was added to each well after the medium was removed. The optical density (OD) values at 490 nm were determined using a microplate spectrophotometer (Multiskan GO, Thermo, Rockford, IL, USA) to calculate the cell viability which was presented as the ratio to the control group.

4.5. EPCs Migration Assay

Migration of EPCs was evaluated by transwell migration assay (BD, San Diego, CA, USA). EPCs were treated as aforementioned. EPCs suspension (200 µL, 1.2 × 10^4 cells/mL in M199 medium) were added to the upper chamber of a 24-well transwell plate with 8 µm pore membrane. M199 and EGM-2MV medium were added to the upper and lower transwell chamber, respectively. After culture at 37 °C with 5% CO₂ for 24 h, a cotton wool swab was used to gently wipe the upper cells that had not migrated, and the lower cells were fixed and stained with DAPI (Sigma, catalog number: D8417). The migratory EPCs in five randomly selected fields of view were analyzed under a fluorescence microscope (×100) (Eclipse TE300, Nikon, Tokyo, Japan).

4.6. Cell Adhesion

After being treated by S1P at 0, 0.1, 0.25, 0.5, 1, and 2 µM, respectively, EPCs were detached using 0.25% trypsin (Solarbio Life Sciences, catalog number: T1300, Beijing, China). After centrifugation and resuspension in EGM-2MV, identical quantity of EPCs (1 × 10^4 cells) were seeded in a fibronectin-coated 24-well plate (Corning, catalog number: 3337) and cultured at 37 °C with 5% CO₂ for 30 min. After incubation, non-adherent cells were gently removed and adherent cells were counted using a phase contrast microscope (Eclipse 80i, Nikon) in five randomly selected fields of view (×100) by three independent blinded investigators.

4.7. Tube Formation Assay

After being treated by S1P at 0, 0.25, 0.5, and 1 µM, respectively, EPCs were detached using 0.25% trypsin. After centrifugation and resuspension in EGM-2MV (Lonza, catalog number: CC-3162), EPCs were seeded in 96-well plates precoated with (BD Bio-science, Stockholm, Sweden, catalog number: 354230) at a density of 1.0 × 10^4 cells/well and cultured at 37 °C with 5% CO₂ for 8 h. A microscope (×40) (Nikon) was used to detect the tube formation in five randomly selected microscopic fields of view. The average total length of tubes with tubular structures (exceeding approximately six cells in length) was analyzed by Image-Pro Plus (version 5.1, Media cybernetics, Silver Spring, MD, USA). The total length of tubes (% of control) was compared among the groups.

4.8. Detection of NO in Medium

After being treated by S1P at 0, 0.1, 0.25, 0.5, 1, and 2 µM, respectively, a nitric oxide (NO) assay kit (Jiancheng, Nanjing, China, catalog number: A012-1-2) was used to detect the concentration of NO released from EPCs. In brief, 100 µL supernatants from cultured EPCs were harvested and the levels
of NO released by EPCs were quantified based on colorimetric assay at 550 nm using a microplate spectrophotometer (Multiskan GO, Thermo, Rockford, IL, USA). The NO-releasing ability of EPCs was calculated as the ratio of NO to total protein (µM/µg). And the total protein concentration was measured by the BCA method.

4.9. Western Blot Analyses

Radio immunoprecipitation assay (RIPA, Solarbio, catalog number: R0010) lysis buffer equipped with phenylmethylsulfonyl fluoride (PMSF, final concentration at 1%) and supplemented with protein phosphatase inhibitor (Solarbio, catalog number: P1260) was used to extract total protein. Equal amounts of total proteins (30 µg) for each well were loaded and isolated by 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) electrophoresis. Then the proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane. After being blocked with 5% FBS for 2 h at room temperature, the membranes were incubated with primary antibodies against β-actin (1:5000, Sigma, catalog number: A5441), AKT (1:1000, CST, catalog number: #2920), p-AKT (1:5000, Abcam, catalog number: ab81283), eNOS (1:300, Santa Cruz, catalog number: sc-8311), and p-eNOS (1:500, Santa Cruz, catalog number: sc-21871-R) overnight at 4 °C under constant shaking. After being washed with PBS buffer three times (5 min each), the membranes were incubated with the secondary antibodies conjugated to horseradish peroxidase (HRP) (1:2000, Santa Cruz, catalog number: sc-2004 or sc-2005) for 2 h at room temperature under constant shaking. After washing the membrane with PBS buffer three times (5 min each), an ECL chemiluminescence detection kit (catalog number PE0010, Solarbio, Beijing, China) and a chemiluminescence gel imaging system (FluorChem Q, ProteinSimple, San Jose, CA, USA) were used to visualize the immunoproteins complexes, and protein band intensities were analyzed by Image-Pro Plus software (version 5.1, Media cybernetics, Silver Spring, MD, USA), with β-actin as internal reference.

4.10. Statistical Analysis

All data are represented as means ± SD (standard deviation). Statistical analyses were conducted by One-way ANOVA, with Student-Newmann-Keuls post-hoc test for multiple comparisons using the SPSS software of version 17.0 (SPSS Inc., Chicago, IL, USA). A \( p < 0.05 \) value was considered statistically significant.

Supplementary Materials: The following are available online, Figure S1: Effects of LY294002 or L-NAME on cell viability of EPCs

Author Contributions: Conceptualization, T.Z. and N.Y.; methodology, X.W., E.Z., G.L., and N.Y.; validation, X.W., E.Z., and N.Y.; investigation, X.W., E.Z., G.L., and Q.M.; analysis, X.W., G.L., T.Z., and N.Y.; writing—original draft preparation, X.W., E.Z., T.Z., and N.Y.; writing—review and editing, X.W., E.Z., G.L., Q.M., T.Z., and N.Y.; supervision, T.Z. and N.Y.; funding acquisition, N.Y. All authors read and approved the content of the manuscript.

Funding: This study was supported by the National Natural Science Foundation of China (No. 81600360), the Province Natural Science Foundation of Shandong (No. ZR2012HL18), the Province Science and Technology Development Foundation of Shandong (2014GSF118105), the Province Higher University Science and Technology Development Project of Shandong (No. J14LK03), and the Province Medical Science and Technology Development Project of Shandong (No. 2017WSB32011).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Schwartz, B.G.; Economides, C.; Mayeda, G.S.; Burstein, S.; Kloner, R.A. The endothelial cell in health and disease: Its function, dysfunction, measurement and therapy. Int. J. Impot. Res. 2010, 22, 77–90. [CrossRef] [PubMed]
2. Xu, J.Y.; Lee, Y.K.; Wang, Y.; Tse, H.F. Therapeutic application of endothelial progenitor cells for treatment of cardiovascular diseases. Curr. Stem Cell Res. Ther. 2014, 9, 401–414. [CrossRef] [PubMed]
4. Naito, H.; Kidoya, H.; Sakimoto, S.; Wakabayashi, T.; Takakura, N. Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels. EMBO J. 2012, 31, 842–855. [CrossRef] [PubMed]

5. Bitterli, L.; Afan, S.; Bühler, S.; DiSanto, S.; Zwahlen, M.; Schmidlin, K.; Yang, Z.; Baumgartner, I.; Diehm, N.; Kalka, C. Endothelial progenitor cells as a biological marker of peripheral artery disease. Vasc. Med. 2016, 21, 3–11. [CrossRef]

6. Georgescu, A.; Alexandru, N.; Andrei, E.; Dragan, E.; Cochior, D.; Dias, S. Effects of transplanted circulating endothelial progenitor cells and platelet microparticles in atherosclerosis development. Biol. Cell 2016, 108, 219–243. [CrossRef]

7. Gandy, K.A.; Obeid, L.M. Regulation of the sphingosine kinase/sphingosine 1-phosphate pathway. Handb. Exp. Pharmacol. 2013, 216, 275–303.

8. Maceyka, M.; Spiegel, S. Sphingolipid metabolites in inflammatory disease. Nature 2014, 510, 58–67. [CrossRef]

9. Zhao, J.; Garcia, D.; Gartung, A.; Lee, M.J. Sphingosine-1-phosphate receptor subtype 2 signaling in endothelial senescence-associated functional impairments and inflammation. Curr. Atheroscler. Rep. 2015, 17, 504. [CrossRef]

10. Daum, G.; Grabski, A.; Reidy, M.A. Sphingosine1-phosphate: A regulator of arterial lesions. Thromb. Vasc. Biol. 2009, 29, 1439–1443. [CrossRef]

11. Seeger, F.H.; Haendeler, J.; Walter, D.H.; Rochwalsky, U.; Reinhold, J.; Urbich, C.; Rössig, L.; Corbaz, A.; Chvatchko, Y.; Zeiher, A.M.; et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 2005, 111, 1184–1191. [CrossRef] [PubMed]

12. Walter, D.H.; Haendeler, J.; Reinhold, J.; Rochwalsky, U.; Seeger, F.; Honold, J.; Hoffmann, J.; Urbich, C.; Lehmann, R.; Arenzana-Seisdedos, F.; et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ. Res. 2005, 97, 1142–1151. [CrossRef] [PubMed]

13. Walter, D.H.; Rochwalsky, U.; Reinhold, J.; Seeger, F.; Aicher, A.; Urbich, C.; Spyridopoulos, I.; Chun, J.; Brinkmann, V.; Keul, P.; et al. Sphingosine-1-Phosphate Stimulates the Functional Capacity of Progenitor Cells by Activation of the CXCR4-Dependent Signaling Pathway via the S1P3 Receptor. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 275–282. [CrossRef] [PubMed]

14. Son, B.R.; Marquez-Curtis, L.A.; Kucia, M.; Wysockznski, M.; Turner, A.R.; Ratajczak, J.; Ratajczak, M.Z.; Janowska-Wieczorek, A. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006, 24, 1254–1264. [CrossRef] [PubMed]

15. Haynes, M.P.; Li, L.; Sinha, D.; Russell, K.S.; Hisamoto, K.; Baron, R.; Collinge, M.; Sessa, W.C.; Bender, J.R. Src kinase mediates sphingosine 1-phosphate pathway. Mol. Cell Biochem. 2013, 377, 229–236. [CrossRef]

16. Kwon, S.M.; Lee, J.H.; Lee, S.H.; Jung, S.Y.; Kim, D.Y.; Kang, S.H.; Yoo, S.Y.; Hong, J.K.; Park, J.H.; Kim, J.H.; et al. Cross talk with hematopoietic cells regulates the endothelial progenitor cell differentiation of CD34 positive cells. PLoS ONE 2014, 9, e106310. [CrossRef]

17. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964–967. [CrossRef]

18. Winkler, M.S.; Nierhaus, A.; Poppe, A.; Greiwe, G.; Gräler, M.H.; Daum, G. Sphingosine-1-Phosphate: A Potential Biomarker and Therapeutic Target for Endothelial Dysfunction and Sepsis? Shock 2017, 47, 666–672. [CrossRef]
21. Yang, S.W.; Hennessy, R.R.; Khosla, S.; Lennon, R.; Loeffler, D.; Sun, T.; Liu, Z.; Park, K.H.; Wang, F.L.; Lerman, L.O.; et al. Circulating osteogenic endothelial progenitor cells: New biomarker for the severity of coronary artery disease. *Int. J. Cardiol.* 2017, 227, 833–839. [CrossRef] [PubMed]

22. Asahara, T.; Kawamoto, A.; Masuda, H. Concise review: Circulating endothelial progenitor cells for vascular medicine. *Stem Cells* 2011, 29, 1650–1655. [CrossRef] [PubMed]

23. Haider, K.H.; Aziz, S.; Al-Reshidi, M.A. Endothelial progenitor cells for cellular angiogenesis and repair: Lessons learned from experimental animal models. *Regen. Med.* 2017, 12, 969–982. [CrossRef] [PubMed]

24. Watt, J.; Kennedy, S.; Ahmed, N.; Hayhurst, J.; McClure, J.D.; Berry, C.; Wadsworth, R.M.; Oldroyd, K.G. The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. *Open Heart* 2016, 3, e000342. [CrossRef] [PubMed]

25. Sattler, K.J.; Elbasan, S.; Keul, P.; Elter-Schulz, M.; Bode, C.; Gröber-Preuss, M.; Budde, T.; Erbel, R.; Heusch, G.; et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. *Basic Res. Cardiol.* 2010, 105, 821–832. [CrossRef] [PubMed]

26. Vasa, M.; Fichtlscherer, S.; Aicher, A.; Adler, K.; Urbich, C.; Martin, H.; Zeiher, A.M.; Dimmelber, S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ. Res.* 2001, 89, e1–e7. [CrossRef] [PubMed]

27. Tepper, O.M.; Galiano, R.D.; Capla, J.M.; Kalka, C.; Gagne, P.J.; Jacobowitz, G.R.; Levine, J.P.; Gurtner, G.C. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. *Circulation* 2002, 106, 2781–2786. [CrossRef] [PubMed]

28. Hiroki, J.; Shimokawa, H.; Higashi, M.; Morikawa, K.; Kandabashi, T.; Kawamura, N.; Kubota, T.; Ichiki, T.; Amano, M.; Kaibuchi, K.; et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. *J. Mol. Cell Cardiol.* 2004, 37, 537–546. [CrossRef]

29. Napoli, C.; Nigris, F.D.; Williams-Ignarro, S.; Pignalosa, O.; Sica, V.; Ignarro, L.J. Nitric oxide and atherosclerosis: An update. *Nitric Oxide* 2000, 15265–15279. [CrossRef]

30. Kitahara, M.; Kanaki, T.; Ishii, I.; Saito, Y. Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin. *Br. J. Pharmacol.* 2010, 119, 1418–1428. [CrossRef]

31. Eberhardt, R.T.; Loscalzo, J. Nitric oxide in atherosclerosis: Nitric oxide and the cardiovascular system. *Humana Press* 2000, 273–295.

32. Maceyka, M.; Harikumar, K.B.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate signaling and its role in disease. *Trends Cell Biol.* 2012, 22, 50–60. [CrossRef] [PubMed]

33. Rosen, H.; Stevens, R.C.; Hanson, M.; Roberts, E.; Oldstone, M.B. Sphingosine-1-Phosphate and Its Receptors: Structure, Signaling, and Influence. *Annu. Rev. Biochem.* 2013, 82, 637–662. [CrossRef]

34. Soltau, I.; Madersbach, E.; Geissens, M.; Schwedhelm, E.; Winkler, M.S.; Geffen, M.; Peine, S.; Schoen, G.; Debus, E.S.; Larena-Avellaneda, A.; et al. Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans. *PLoS ONE* 2016, 11, e0168302. [CrossRef] [PubMed]

35. Kimura, T.; Boehmler, A.M.; Seitz, G.; Kuçi, S.; Wiesner, T.; Brinkmann, V.; Kanz, L.; Möhle, R. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34 progenitor cells. *Blood* 2004, 103, 4478–4486. [CrossRef] [PubMed]

36. Zhao, Y.D.; Ohkawara, H.; Rehman, J.; Wary, K.K.; Vogel, S.M.; Minshall, R.D.; Zhao, Y.Y.; Malik, A.B. Bone marrow progenitor cells induce endothelial adherens junction integrity by sphingosine-1-phosphate-mediated Rac1 and Cdc42 signaling. *Circ. Res.* 2009, 105, 696–704. [CrossRef] [PubMed]

37. Wang, H.; Cai, K.Y.; Li, W.; Huang, H. Sphingosine-1-Phosphate Induces the Migration and Angiogenesis of Epchos Through the Akt Signaling Pathway via Sphingosine-1-Phosphate Receptor 3/Platelet-Derived Growth Factor Receptor-β. *Cell Mol. Biol. Lett.* 2015, 20, 597–611. [CrossRef]

38. Poitevin, S.; Cussac, D.; Leroyer, A.S.; Albinet, V.; Sarlon-Bartoli, G.; Guillet, B.; Hubert, L.; Andrieu-Abadie, N.; Coudere, B.; Parini, A.; et al. Sphingosine kinase 1 expressed by endothelial colony-forming cells has a critical role in their revascularization activity. *Cardiovasc. Res.* 2014, 103, 121–130. [CrossRef]

39. Everaert, B.R.; Van Craenenbroeck, E.M.; Hoymans, V.Y.; Haine, S.E.; Van Nassauw, L.; Conraads, V.M.; Timmermans, J.P.; Vrints, C.J. Current perspective of pathophysiological and interventional effects on endothelial progenitor cell biology: Focus on PI3K/AKT/eNOS pathway. *Int. J. Cardiol.* 2010, 144, 350–366. [CrossRef]
40. Katusic, Z.S.; Austin, S.A. Endothelial nitric oxide: Protector of a healthy mind. *Eur. Heart J.* 2014, 35, 888–894. [CrossRef]

41. Morales-Ruiz, M.; Lee, M.J.; Zöllner, S.; Gratton, J.P.; Scotland, R.; Shiojima, I.; Walsh, K.; Hla, T.; Sessa, W.C. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a gi protein/phosphoinositide 3-kinase pathway in endothelial cells. *J. Biol. Chem.* 2001, 276, 19672–19677. [CrossRef] [PubMed]

42. Wang, H.; Huang, H.; Ding, S.F. Sphingosine-1-phosphate promotes the proliferation and attenuates apoptosis of Endothelial progenitor cells via S1PR1/S1PR3/PI3K/Akt pathway. *Cell Biol Int.* 2018, 42, 1492–1502. [CrossRef] [PubMed]

43. Nakagawa, H.; Nihonmatsu, N.; Ohta, S.; Hirobe, M. Effects of new endogenous nonprotein amino acids, 1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid derivatives, on behavior of mice. *Biochem. Biophys. Res. Commun.* 1996, 225, 1027–1034. [CrossRef] [PubMed]

44. Robinson, E.S.; Anderson, N.J.; Crosby, J.; Nutt, D.J.; Hudson, A.L. Endogenous beta-carbolines as clonidine-displacing substances. *Ann. N. Y. Acad. Sci.* 2003, 1009, 157–166. [CrossRef] [PubMed]

45. Nakagawa, H.; Yamada, M.; Maeda, N.; Iwatsuki, K.; Hirayama, A.; Ikenaka, K. Clinical trial of intrathecal administration of 5-fluoro-2′-deoxyuridine for treatment of meningeal dissemination of malignant tumors. *J. Neurooncol.* 1999, 45, 175–183. [CrossRef]

**Sample Availability:** Samples of the compounds Sphingosine-1-Phosphate, LY294002 and L-NAME are available from the authors.

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).